LIDDS
LIDDS: Another (potential) weapon against cancer (Redeye)
2019-04-23 07:30
Earlier in April LIDDS announced a new project, a Toll-Like Receptor 9 (TLR9) forumlated with the NanoZolid platform. Positive preclinical data have been generated so far and LIDDS aims to start Phase I will in 2020. We have included the new project in our valuation which raising our valuation range slightly.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se